Small stem cells, such as spore-like cells, blastomere-like stem cells (BLSCs), and very-small embryonic-like stem cells (VSELs) have been described in recent studies, although their multipotency in human tissues has not yet been confirmed. Here, we report the discovery of adult multipotent stem cells derived from human bone marrow, which we call StemBios (SB) cells. These isolated SB cells are smaller than 6 ìm and are DAPI+ and Lgr5+ (Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5). Because Lgr5 has been characterized as a stem cell marker in the intestine, we hypothesized that SB cells may have a similar function. In vivo cell tracking assays confirmed that SB cells give rise to three types of cells, and in vitro studies demonstrated that SB cells cultured in proprietary media are able to grow to 6–25 ìm in size. Once the SB cells have attached to the wells, they differentiate into different cell lineages upon exposure to specific differentiation media. We are the first to demonstrate that stem cells smaller than 6 ìm can differentiate both in vivo and in vitro. In the future, we hope that SB cells will be used therapeutically to cure degenerative diseases.

No abstract

In this study, we find a subject with a deficiency of IL-1 receptor antagonist (DIRA) -like syndrome who also has symptoms similar to that of psoriasis. Within 24 hours of intravenous infusion with autologous SB cells®, the subject's IL-1 RA expression is shown to increase drastically, during which the subject experiences relief from his psoriasis-like symptoms.The subject was diagnosed with psoriasis as a young adult; however, no treatment has offered relief for the psoriatic plaques located along his forearms and back. Currently his diagnosis is classified as psoriasis and his management of the disease is minimal. Throughout the course of SB cell® treatments, we used ELISA to monitor a panel of cytokines, it was here we noticed the subject's deficient IL-1RA expression without treatment, his expression levels were near 0 pg/ml. 24 Hours after treatment, measurements of his expression levels were increased several thousand fold. This case presents the possibility that SB cells can act as a treatment for psoriasis due to IL-1 RA deficiency.

Aims: Dementia is characterized by cognitive decline and memory loss, as well as impairment in short-term memory, long-term memory, and judgement. The cognitive deficits associated with dementia can interfere significantly with their social relationships and activities, as well as their occupational functioning. We believe that our SB cell® therapy may be the next step in treating non-Alzheimer's dementia. Presentation of Case:We describe four patients who have been diagnosed with non-Alzheimer's dementia and have experienced significant improvements in their memory, mood, cognitive functioning, and ability to do daily tasks after receiving our SB cells® treatment.Discussion: Patients receiving our stem cell therapy showed a significant decrease in CD10 expression, a marker for NEP. It suggested that there may be a beneficial effect of pharmaceutical inhibition of cerebral NEP on learning and memory due to the accumulation of peptides other than Aβ degradable by NEP. Conclusion:Our study may validate the existence of peptides targeted by NEP that may improve learning and provide a promising avenue to the treatment of non-Alzheimer's dementia. We hoped to continue investigating new patient cases to determine the potential CD10 has as a genetic marker of dementia.

Inflammantory back pain is a common symptom in Ankylosing spondylitis patients [1]. Since there is no cure for the disease, current treatment focuses on lower the symptoms and preventing progression of the disease [2]. Many laboratories had tried to use stem cell to teat Ankylosing spondylitis related symptoms and receive positive response from patients. Here we used SB cells ® to treat Ankylosing spondylitis patients. Not only patients showed lower pain symptom, but also patients did not report any side effect from the treatment. Here we used the SB cells ® which purified from patients' own body in their stem cell treatment. With our initial success, we are planning to perform SB cells ® treatment on a larger scale of Ankylosing spondylitis patients in the hope of obtaining larger data volume.